Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology Forms Alliance with World Leading Translational Research Centres

Published: Monday, January 21, 2013
Last Updated: Monday, January 21, 2013
Bookmark and Share
The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network.

MRC Technology, a technology transfer charity and company, announces it is one of six of the world’s top translational health research centres  that have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. 

The founding organizations are: 

The Centre for Drug Research and Development (CDRD), Canada
Lead Discovery Center (LDC), Germany
The Scripps Research Institute, Scripps Florida, United States
The Centre for Drug Design and Discovery (CD3), KU Leuven R&D, Belgium
Medical Research Council Technology, United Kingdom
Cancer Research Technology, United Kingdom

All member organizations are fully-integrated translational centres capable of professionally advancing drug discovery projects along the value chain from idea to drug candidate with proof-of-concept.  Together, they represent close to 400 experienced drug developers collaborating with tens of thousands of academic scientists around the globe on over 165 highly innovative therapeutic projects targeting significant unmet medical needs. For the biopharmaceutical industry, they represent a major source of innovation. Numerous alliances with many of the industry’s leading global companies have been established to develop resulting drug candidates further and ultimately make them available to patients.

Through this Alliance, member organizations will collaborate on mutually-beneficial projects, share best practices, expertise and resources, and develop common standards and performance measurements – ultimately working together to improve the conversion of global early-stage technology into much needed therapies.

Karimah Es Sabar, President and CEO of CDRD commented, “We see a multitude of translational research initiatives around the world, but until now, these have for the most part, worked in isolation of one another. This Alliance will be a powerful vehicle in bringing such organizations together, leveraging one another’s strengths, and ultimately making for a much more effective global translational research environment.”  

Mike Johnson, MRC Technology’s Director of Corporate Partnerships said: “The shared objectives between MRC Technology and the other members of the Alliance make collaborating rather than competing the obvious way forward. I hope that by working together we can move research from the lab bench to the patient faster and more effectively.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology and Yabao Pharmaceuticals Announce Exclusive Partnership
Partnership in China to develop novel therapeutics for Parkinson’s disease.
Friday, November 28, 2014
Charities Pledge to Inject Millions to Jump Start Drug Development for Brain Diseases
MRC Technology to lead Neurodegeneration Medicines Acceleration Programme to uncover promising drugs in pharma libraries.
Tuesday, November 18, 2014
MRC Technology and Proximagen Collaborate
Project will investigate a small molecule solution for Macrophage migration inhibitory factor.
Monday, October 13, 2014
MRC Technology Sells its MCRs Programme to Pfizer
Small molecules developed in collaboration with Queen Mary University of London.
Thursday, June 19, 2014
MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
Initiative brings together global expertise to streamline drug discovery.
Wednesday, May 14, 2014
MRC Technology and EMBLEM Collaborate to Streamline Drug Development
Initiative strengthens drug development and commercialization network.
Monday, April 15, 2013
MRC Technology and CAS Collaborate to Identify New Targets for Drug Discovery
Initiative brings together global expertise to streamline drug discovery.
Friday, November 30, 2012
MRC Technology Launches Small Molecule Compound Library Access Scheme
Subset of compound library to be made available to academic researchers free of charge.
Thursday, September 20, 2012
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!